Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer

Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 126; no. 23; pp. 4510 - 4516
Main Authors ZENG, Xiao-li, ZHANG, Shao-yan, ZHENG, Jun-fang, YUAN, Hui, WANG, Yan
Format Journal Article
LanguageEnglish
Published China Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China 05.12.2013
Subjects
Online AccessGet full text
ISSN0366-6999
2542-5641
2542-5641
DOI10.3760/cma.j.issn.0366-6999.20122931

Cover

Abstract Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.
AbstractList Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.
Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality. Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.BACKGROUNDSensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality. Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals, and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.METHODSThe levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals, and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR. MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P < 0.0001). MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P = 0.260). MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P = 0.001). There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell carcinoma patients (P < 0.0001). In receiver operating characteristic curve (ROC) analysis, low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects. High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects. High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma. The miR-150 level was significantly associated with distant metastasis (P = 0.014).RESULTSAll endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR. MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P < 0.0001). MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P = 0.260). MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P = 0.001). There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell carcinoma patients (P < 0.0001). In receiver operating characteristic curve (ROC) analysis, low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects. High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects. High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma. The miR-150 level was significantly associated with distant metastasis (P = 0.014).It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.CONCLUSIONSIt is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.
Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality. Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment. The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC. The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals, and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored. All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR. MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P < 0.0001). MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P = 0.260). MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P = 0.001). There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell carcinoma patients (P < 0.0001). In receiver operating characteristic curve (ROC) analysis, low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects. High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects. High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma. The miR-150 level was significantly associated with distant metastasis (P = 0.014). It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC. Moreover, miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.
Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.
Author ZENG Xiao-li ZHANG Shao-yan ZHENG Jun-fang YUAN Hui WANG Yan
AuthorAffiliation Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China
AuthorAffiliation_xml – name: Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China
Author_xml – sequence: 1
  givenname: Xiao-li
  surname: ZENG
  fullname: ZENG, Xiao-li
– sequence: 2
  givenname: Shao-yan
  surname: ZHANG
  fullname: ZHANG, Shao-yan
– sequence: 3
  givenname: Jun-fang
  surname: ZHENG
  fullname: ZHENG, Jun-fang
– sequence: 4
  givenname: Hui
  surname: YUAN
  fullname: YUAN, Hui
– sequence: 5
  givenname: Yan
  surname: WANG
  fullname: WANG, Yan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24286416$$D View this record in MEDLINE/PubMed
BookMark eNqVkc1u1DAURi1URKeFV0BmAWKTwbEdJ1lQqRrxJ1VCQrC27jj2jCPHTu1EZXh6HGamC1awshfnfvruuVfowgevEXpdkjWrBXmnBlj3a5uSXxMmRCHatl1TUlLasvIJWtGK06ISvLxAq0fgEl2l1BNCq6oWz9Al5bTJiFihw62bdNQdHuy3ouQMgz_9K4L1zzHqlGzwCVuPRx3tuNcRHN66EDIXcrlZOQ0RK-1cwiZE3FnY-ZBswsHgDBRpAOf-ANjNfocVeKXjc_TUgEv6xem9Rj8-fvi--Vzcff30ZXN7VyjO6qkoSSUqRpiuRbcVoq0rMA2FxnRABGu6LauampFaKaOb0tBWEEM01Ary4lBTdo1ujrmzH-HwkKvIMdoB4kGWRC5OZXYqe7k4lYsyuSiTZ6c54M0x4AG8Ab-TfZijz5Xlr70a-swxygglGXx7BMcY7medJjnYtKwNXoc5yZILWgvOBc_oyxM6bwfdPTY6HyYD74-AiiGlqM1_l978Na_sBFM-5RTBun9OeXVK2Qe_u7d5-XMN3jBKaVOx3wuhx_k
CitedBy_id crossref_primary_10_3109_1354750X_2016_1153724
crossref_primary_10_3892_etm_2016_3555
crossref_primary_10_18632_oncotarget_21644
crossref_primary_10_1002_jcb_29214
crossref_primary_10_1080_13813455_2020_1752257
crossref_primary_10_3390_genes10030185
crossref_primary_10_1080_07853890_2021_2000634
crossref_primary_10_3390_cancers15194774
crossref_primary_10_3390_ijms150711973
crossref_primary_10_1038_s41598_018_25900_z
crossref_primary_10_1371_journal_pone_0134220
crossref_primary_10_1016_j_bbagen_2014_11_023
crossref_primary_10_1111_resp_12444
crossref_primary_10_1186_s12867_015_0052_6
crossref_primary_10_1089_dna_2019_4796
crossref_primary_10_1017_S0007114516001173
crossref_primary_10_1007_s12032_016_0815_z
crossref_primary_10_1007_s13277_014_2188_2
crossref_primary_10_1155_2018_5930951
crossref_primary_10_23736_S2784_8477_21_01970_7
crossref_primary_10_3892_ol_2015_3170
crossref_primary_10_1007_s13277_014_2330_1
crossref_primary_10_3390_molecules19068220
crossref_primary_10_1016_j_gene_2015_07_015
crossref_primary_10_1039_C5MB00364D
Cites_doi 10.1186/1476-4598-9-136
10.1155/2011/732690
10.1373/clinchem.2010.157198
10.1093/nar/gni178
10.2174/092986709787581833
10.1158/1078-0432.CCR-09-2638
10.1016/j.cca.2010.02.074
10.1038/sj.onc.1209913
10.1016/j.juro.2008.10.149
10.1038/leu.2011.81
10.1093/carcin/bgr223
10.1210/jc.2008-1451
10.1016/j.bbrc.2009.12.182
10.3816/CLC.2009.n.006
10.1038/nature02871
10.3322/caac.20006
10.1101/gad.1399806
10.1001/jama.297.9.953
10.1016/j.ccr.2006.01.025
10.1159/000113489
10.1159/000218166
10.1016/j.biopha.2010.01.018
10.1016/j.biocel.2009.12.014
10.1200/JCO.2009.24.9342
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
2B.
4A8
92I
93N
PSX
TCJ
ADTOC
UNPAY
DOI 10.3760/cma.j.issn.0366-6999.20122931
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer
EISSN 2542-5641
EndPage 4516
ExternalDocumentID 10.3760/cma.j.issn.0366-6999.20122931
zhcmj201323020
24286416
10_3760_cma_j_issn_0366_6999_20122931
48322285
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: This study was supported by grants from the National Natural Science Foundation of China; the Cooperative Research Project of Foundation and Clinic from Capital Medical University
  funderid: (30900247); (11JL48)
GroupedDBID ---
-05
-0E
-SE
-S~
.55
.GJ
29B
2B.
2C~
2RA
2WC
3V.
40I
53G
5GY
5RE
5VR
5VS
6J9
7X7
88E
8FI
8FJ
92F
92I
92L
92M
93N
93R
9D9
9DE
AAHPQ
AASCR
ABASU
ABCQX
ABDIG
ABUWG
ABVCZ
ABXLX
ACGFO
ACGFS
ACILI
ADGGA
ADHPY
ADPDF
ADRAZ
AENEX
AFDTB
AFKRA
AFUIB
AHMBA
AHVBC
AINUH
AJIOK
AJNWD
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
ANFDX
AOHHW
BENPR
BPHCQ
BVXVI
C1A
CAJEE
CAJUS
CCEZO
CCPQU
CHBEP
CIEJG
CQIGP
CW9
DIK
DIWNM
EBS
EEVPB
EJD
F5P
FA0
FCALG
FRP
FYUFA
GNXGY
GQDEL
GROUPED_DOAJ
GX1
HLJTE
HMCUK
HYE
IAO
IHR
IHW
IKREB
INH
INR
IPNFZ
ITC
JUIAU
KQ8
L7B
M1P
M48
OK1
OPUJH
OVD
OVDNE
OVEED
OXXIT
P2P
P6G
PIMPY
PQQKQ
PROAC
PSQYO
PV9
Q--
Q-4
R-E
RIG
RLZ
RNS
RPM
RT5
RZL
S..
T8U
TCJ
TEORI
TGQ
TR2
TSPGW
U1F
U1G
U5E
U5O
UKHRP
W2D
W91
WFFXF
X7J
X7M
XSB
ZA5
ZGI
ZXP
~WA
0R~
AAAAV
AAIQE
AAYXX
ABZZY
ACXJB
ADKSD
AFBFQ
AHQNM
AJCLO
AJZMW
AKCTQ
ALKUP
AOQMC
BQLVK
CITATION
OVT
ALIPV
CGR
CUY
CVF
ECM
EIF
H13
NPM
PHGZM
PHGZT
PJZUB
PPXIY
7X8
4A8
PMFND
PSX
ADTOC
PUEGO
UNPAY
ID FETCH-LOGICAL-c437t-10565303e76db66975af82a8fda0638db3587307ccfe81f2960f0ea7ca699a723
IEDL.DBID UNPAY
ISSN 0366-6999
2542-5641
IngestDate Mon Sep 15 10:19:55 EDT 2025
Thu May 29 03:55:56 EDT 2025
Thu Oct 02 08:06:39 EDT 2025
Mon Jul 21 05:55:47 EDT 2025
Thu Apr 24 23:02:10 EDT 2025
Wed Oct 01 03:41:25 EDT 2025
Wed Feb 14 10:39:00 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 23
Keywords microRNA
diagnosis
carcinoma,non-small cell lung
Language English
License cc-by-nc-nd
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c437t-10565303e76db66975af82a8fda0638db3587307ccfe81f2960f0ea7ca699a723
Notes 11-2154/R
Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and reduce the mortality.Small non-coding microRNAs (miRNAs) are key components of cancer development and are considered as potential biomarkers for cancer diagnosis and for monitoring treatment.The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in peripheral blood mononuclear cells (PBMC) for the diagnosis of NSCLC.Methods The levels of two mature miRNAs (miR-143 and miR-150) were detected by probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in PBMC of 64 patients with NSCLC and 26 healthy individuals,and the relationship between miR-143 and miR-150 levels and clinical and pathological factors was explored.Results All endogenous miRNAs were present in peripheral blood in a remarkably stable form and detected by RT-qPCR.MiR-143 expression in the PBMC specimens was significantly lower in NSCLC patients than in healthy individuals (P <0.0001).MiR-150 expression in the PBMC specimens was not significantly different between NSCLC patients and healthy individuals (P=0.260).MiR-150 expression was significantly higher in lung adenocarcinoma patients than in healthy individuals (P=0.001).There was a very strong difference in the expression level of miR-150 between lung adenocarcinoma patients and lung squamous cell caminoma patients (P <0.0001).In receiver operating characteristic curve (ROC) analysis,low expression of miR-143 showed the area under the ROC (AUC) of 0.885 for distinguishing cancer patients from healthy subjects.High expression of miR-150 had an AUC of 0.834 for distinguishing lung adenocarcinoma patients from healthy subjects.High expression of miR-150 had an AUC of 0.951 for distinguishing lung adenocarcinoma from lung squamous cell carcinoma.The miR-150 level was significantly associated with distant metastasis (P=0.014).Conclusions It is indicated that there is a potential for using miR-143 as a novel diagnostic biomarker for NSCLC.Moreover,miR-150 can be a highly accurate marker for differentiating adenocarcinoma from squamous cell carcinoma.
microRNA;carcinoma,non-small cell lung;diagnosis
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://doi.org/10.3760/cma.j.issn.0366-6999.20122931
PMID 24286416
PQID 1462764464
PQPubID 23479
PageCount 7
ParticipantIDs unpaywall_primary_10_3760_cma_j_issn_0366_6999_20122931
wanfang_journals_zhcmj201323020
proquest_miscellaneous_1462764464
pubmed_primary_24286416
crossref_primary_10_3760_cma_j_issn_0366_6999_20122931
crossref_citationtrail_10_3760_cma_j_issn_0366_6999_20122931
chongqing_primary_48322285
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-12-05
PublicationDateYYYYMMDD 2013-12-05
PublicationDate_xml – month: 12
  year: 2013
  text: 2013-12-05
  day: 05
PublicationDecade 2010
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Chinese medical journal
PublicationTitleAlternate Chinese Medical Journal
PublicationTitle_FL Chinese Medical Journal
PublicationYear 2013
Publisher Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China
Publisher_xml – name: Department of Clinical Laboratory Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Thoracic Surgery Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China%Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, China
References Ortholan (R19-20-20240102) 2009; 16
Lin (R12-20-20240102) 2011; 25
Takagi (R10-20-20240102) 2009; 77
Yanaihara (R18-20-20240102) 2006; 9
Hu (R25-20-20240102) 2010; 28
Valencia-Sanchez (R4-20-20240102) 2006; 20
Chen (R20-20-20240102) 2005; 33
Wu (R22-20-20240102) 2011; 124
Watanabe (R15-20-20240102) 2011; 25
Wu (R13-20-20240102) 2010; 392
Slaby (R8-20-20240102) 2007; 72
Gao (R28-20-20240102) 2010; 64
McDonald (R23-20-20240102) 2011; 57
Rabinowits (R27-20-20240102) 2009; 10
Lulla (R14-20-20240102) 2011; 2011
Bi (R21-20-20240102) 2011; 124
Zhang (R26-20-20240102) 2010; 411
Lin (R9-20-20240102) 2009; 181
Bach (R3-20-20240102) 2007; 297
Bishop (R24-20-20240102) 2010; 16
Srivastava (R17-20-20240102) 2011; 32
Iio (R11-20-20240102) 2010; 9
Amaral (R16-20-20240102) 2009; 94
Jemal (R1-20-20240102) 2009; 59
Kent (R6-20-20240102) 2006; 25
Cho (R7-20-20240102) 2010; 42
Ambros (R5-20-20240102) 2004; 431
References_xml – volume: 9
  start-page: 136
  year: 2010
  ident: R11-20-20240102
  article-title: Identification of non-coding RNAs embracing microRNA-143145 cluster.
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-9-136
– volume: 124
  start-page: 2616
  year: 2011
  ident: R22-20-20240102
  article-title: MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
  publication-title: Chin Med J
– volume: 2011
  start-page: 732690
  year: 2011
  ident: R14-20-20240102
  article-title: Identification of differentially expressed microRNAs in Osteosarcoma.
  publication-title: Sarcoma
  doi: 10.1155/2011/732690
– volume: 57
  start-page: 833
  year: 2011
  ident: R23-20-20240102
  article-title: Analysis of circulating microRNA: preanalytical and analytical challenges.
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2010.157198
– volume: 33
  start-page: e179
  year: 2005
  ident: R20-20-20240102
  article-title: Real-time quantification of microRNAs by stem-loop RT-PCR.
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gni178
– volume: 16
  start-page: 1047
  year: 2009
  ident: R19-20-20240102
  article-title: MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets.
  publication-title: Curr Med Chem
  doi: 10.2174/092986709787581833
– volume: 16
  start-page: 610
  year: 2010
  ident: R24-20-20240102
  article-title: Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach.
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-2638
– volume: 411
  start-page: 846
  year: 2010
  ident: R26-20-20240102
  article-title: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2010.02.074
– volume: 25
  start-page: 6188
  year: 2006
  ident: R6-20-20240102
  article-title: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209913
– volume: 181
  start-page: 1372
  year: 2009
  ident: R9-20-20240102
  article-title: MicroRNA-143 as a tumor suppressor for bladder cancer.
  publication-title: J Urol
  doi: 10.1016/j.juro.2008.10.149
– volume: 25
  start-page: 1324
  year: 2011
  ident: R15-20-20240102
  article-title: The role of microRNA-150 as a tumor suppressor in malignant lymphoma.
  publication-title: Leukemia
  doi: 10.1038/leu.2011.81
– volume: 32
  start-page: 1832
  year: 2011
  ident: R17-20-20240102
  article-title: MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells.
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgr223
– volume: 94
  start-page: 320
  year: 2009
  ident: R16-20-20240102
  article-title: MicroRNAs differentially expressed in ACTH-secreting pituitary tumors.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2008-1451
– volume: 392
  start-page: 340
  year: 2010
  ident: R13-20-20240102
  article-title: MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2.
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.12.182
– volume: 10
  start-page: 42
  year: 2009
  ident: R27-20-20240102
  article-title: Exosomal microRNA: a diagnostic marker for lung cancer.
  publication-title: Clin Lung Cancer
  doi: 10.3816/CLC.2009.n.006
– volume: 431
  start-page: 350
  year: 2004
  ident: R5-20-20240102
  article-title: The functions of animal microRNAs.
  publication-title: Nature
  doi: 10.1038/nature02871
– volume: 59
  start-page: 225
  year: 2009
  ident: R1-20-20240102
  article-title: Cancer statistics, 2009.
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20006
– volume: 20
  start-page: 515
  year: 2006
  ident: R4-20-20240102
  article-title: Control of translation and mRNA degradation by miRNAs and siRNAs.
  publication-title: Genes Dev
  doi: 10.1101/gad.1399806
– volume: 297
  start-page: 953
  year: 2007
  ident: R3-20-20240102
  article-title: Computed tomography screening and lung cancer outcomes.
  publication-title: JAMA
  doi: 10.1001/jama.297.9.953
– volume: 9
  start-page: 189
  year: 2006
  ident: R18-20-20240102
  article-title: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2006.01.025
– volume: 72
  start-page: 397
  year: 2007
  ident: R8-20-20240102
  article-title: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer.
  publication-title: Oncology
  doi: 10.1159/000113489
– volume: 77
  start-page: 12
  year: 2009
  ident: R10-20-20240102
  article-title: Decreased expression of microRNA-143 and -145 in human gastric cancers.
  publication-title: Oncology
  doi: 10.1159/000218166
– volume: 64
  start-page: 399
  year: 2010
  ident: R28-20-20240102
  article-title: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2010.01.018
– volume: 25
  start-page: 739
  year: 2011
  ident: R12-20-20240102
  article-title: MicroRNA expression profiles in human colorectal cancers with liver metastases.
  publication-title: Oncol Rep
– volume: 42
  start-page: 1273
  year: 2010
  ident: R7-20-20240102
  article-title: MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2009.12.014
– volume: 124
  start-page: 3164
  year: 2011
  ident: R21-20-20240102
  article-title: miRNA deregulation in multiple myeloma.
  publication-title: Chin Med J
– volume: 28
  start-page: 721
  year: 2010
  ident: R25-20-20240102
  article-title: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-smallcell lung cancer.
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.9342
SSID ssj0025576
Score 2.1788034
Snippet Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic...
Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic outcome and...
Background Sensitive and specific biomarkers for identifying early stage of non-small cell lung cancer (NSCLC) are urgently needed to improve the therapeutic...
SourceID unpaywall
wanfang
proquest
pubmed
crossref
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 4510
SubjectTerms Aged
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Leukocytes, Mononuclear - metabolism
Male
MicroRNAs - genetics
Middle Aged
miRNA
外周血单个核细胞
外周血单核细胞
小分子RNA
生物标志物
诊断
非小细胞肺癌
鳞状细胞癌
Title Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer
URI http://lib.cqvip.com/qk/85656X/201323/48322285.html
https://www.ncbi.nlm.nih.gov/pubmed/24286416
https://www.proquest.com/docview/1462764464
https://d.wanfangdata.com.cn/periodical/zhcmj201323020
https://doi.org/10.3760/cma.j.issn.0366-6999.20122931
UnpaywallVersion publishedVersion
Volume 126
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2542-5641
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0025576
  issn: 2542-5641
  databaseCode: KQ8
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2542-5641
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0025576
  issn: 2542-5641
  databaseCode: DOA
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2542-5641
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0025576
  issn: 2542-5641
  databaseCode: GX1
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVOVD
  databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling
  customDbUrl:
  eissn: 2542-5641
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0025576
  issn: 2542-5641
  databaseCode: OVEED
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://ovidsp.ovid.com/
  providerName: Ovid
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VW6niwvuRAsVIcMySOH6kEpcVolRIrRBi0XKyHNtpt-xmy2ZX0P56ZvJYFbi0XKIcnIk8_jzzTWYyBnjFc1-KtHC4kXwSCy_S2OZpGScena3b1z5rimiOjtXhWHycyMkWyP5fmCv5eyrXeOPmdnjW7Ich2loVKyQ0VJDF0U1h0LOtJFLwAWyPjz-NvrV5yXYQHSonBQZaSqQ78Ppa8qi_wumiOvmBXuNPP_UP-cSh6-rcXvy0s1nzv09V2urkims6uANf-0m1FSnfh-tVMXSXf_V7vPGs78LtjqyyUYuue7AVqvuwc9Sl4x_AxYhy7cGz-fRzjJSI2aq7lwkLv7oa26pm04pRR-WmhcGMNcXyDPG_qKibsl0ySh_UDPkz823p37Rmi5LhgLie49ybAWyGhok5gunyIYwP3n95dxh3ZznETmR6hdYemSO6y6CVL5Ta19KWObd56S2RJl9kMkdjo50rA2KF46qWSbDaWZy71Tx7BAN8aXgCjCung5P0AaYUHvlRmvigM15wn8iQhAh2N6toztueHUaQ5eK5jOBtv6zGdV3Q6TCOmcFoiHRvUPcYEZHuDenekO5Nr_sI1ObxXvQ1H3zZY8jgBiat2Sos1jXFXlwjK1UigsctuDaikT_liF8Vgd6g7abvfdFh03TGqTaXp25-xinJlmGwsPvfsp_CLZLSFPfIZzBYLdfhOVK0VbHXfNrA64dJutdtzt8VWC-S
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VW6niwvuR8jISHLMkjh-pxGWFqCqkVgixqJwsx3baLdls2ewK2l_PTB6rApeWWw7ORB5_nvkmMx4DvOa5L0VaONxIPomFF2ls87SME4_O1u1pn7VFNIdH6mAqPh7L4y2Qw1mYK_l7Ktd46-Z2fNbuhzHaWhUrJDRUkMXRTWHQs60kUvARbE-PPk2-dXnJbhBdKicFBlpKpDvw5lryqL_C6aI--YFe408_9Q_5xKHr-txe_LRV1Z73qUtbn1xxTft34Oswqa4i5ft4vSrG7vKvfo83nvVduN2TVTbp0HUPtkJ9H3YO-3T8A7iYUK49eDaffY6REjFb988yYeFXX2NbN2xWM-qo3LYwqFhbLM8Q_4uauinbJaP0QcOQPzPflf7NGrYoGQ6ImznOvR3AKjRMzBFMlw9huv_hy_uDuL_LIXYi0yu09sgc0V0GrXyh1J6Wtsy5zUtviTT5IpM5GhvtXBkQKxxXtUyC1c7i3K3m2SMY4UfDE2BcOR2cpB8wpfDIj9LEB53xgvtEhiREsLtZRXPe9ewwgiwXz2UE74ZlNa7vgk6XcVQGoyHSvUHdY0REujeke0O6N4PuI1Cb1wfR13zx1YAhgxuYtGbrsFg3FHtxjaxUiQged-DaiEb-lCN-VQR6g7abfvdlj03TG6fGXJ66-RmnJFuGwcLuf8t-CrdISlvcI5_BaLVch-dI0VbFi35D_gbrjC2s
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Altered+miR-143+and+miR-150+expressions+in+peripheral+blood+mononuclear+cells+for+diagnosis+of+non-small+cell+lung+cancer&rft.jtitle=%E4%B8%AD%E5%8D%8E%E5%8C%BB%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=ZENG+Xiao-li+ZHANG+Shao-yan+ZHENG+Jun-fang+YUAN+Hui+WANG+Yan&rft.date=2013-12-05&rft.issn=0366-6999&rft.eissn=2542-5641&rft.issue=23&rft.spage=4510&rft.epage=4516&rft_id=info:doi/10.3760%2Fcma.j.issn.0366-6999.20122931&rft.externalDocID=48322285
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85656X%2F85656X.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhcmj%2Fzhcmj.jpg